Cooper Companies (The) (COO)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
$69.61-3.17%
Close 2026-07-08 · 1-day change
Reading COO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track COO free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
Reading COO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track COO free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on sustainable growth and cash flow. The current thesis state is intact, supported by strong recent financial performance, but management execution shows mixed results.
The market currently prices COO at a premium compared to peers, indicating that expectations are somewhat high. There is an expectations gap suggesting that the market anticipates continued strong performance, but this could shift if guidance is cut.
Fundamentals are likely to remain stable in the near term, given strong recent financial results. However, the mixed progress on management priorities, particularly around cash flow and margins, introduces some uncertainty.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. Positive earnings and guidance from these companies could support COO, while any negative shifts could impact its momentum.
Overall, COO's outlook remains cautiously optimistic, but it is sensitive to sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Management rose by 11.5 points (from 60.7 to 72.2).
Yes, our read has strengthened. The latest earnings beat and ongoing sale talks for CooperSurgical are positive developments that enhance cash flow and growth potential. There are no significant threats currently impacting the thesis.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This is the threshold for organic growth guidance. Falling below it may signal weakening demand.
Confirms:Q3 organic revenue growth was below 4.5%.
Disproves:Q3 organic revenue growth reported at or above 4.5%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Higher margins show good execution and cost control.
Confirms:Operating margin was above 27% in Q2.
Disproves:Operating margin reported at or below 27% for Q2.
Why it matters: Updates may show confidence in cash flow and spending plans.
Confirms:They announced more share buybacks beyond the current $873.9 million.
Disproves:No updates or reductions in the share repurchase program.
Why it matters: Reaching this goal would show strong cash flow and help growth plans. It is very important for management.
Confirms:Free cash flow reported at $600 million or more in the fiscal year 2026 results.
Disproves:Free cash flow falls below $500 million for FY 2026.
Why it matters: Higher charges may hurt profits and cash flow. This could lower investor confidence.
Confirms:Charges from lawsuits were above $300 million.
Disproves:Charges from lawsuits were below $300 million.
Why it matters: His experience may improve strategy and operations. This could help long-term value.
Confirms:People liked the board after Keel was appointed.
Disproves:There was negative feedback or issues with board decisions after the appointment.
Why it matters: Keeping this guidance shows strong cash flow. This helps growth and share buybacks.
Confirms:Free cash flow guidance confirmed at $600-$625 million.
Disproves:Free cash flow guidance revised down from $600-$625 million.